Emerald BioStructures

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB have extended a collaboration aimed at identifying multiple targets in the drug discovery process, Emerald announced on Thursday.

The firms achieved a second milestone in their drug discovery pact, which utilizes Emerald's X-ray crystallography platform.

Movers & Shakers

Premium

John Hunt, John McCall, John Mulligan, Lynn Silver

The agreement with NEC, which has purchased an equity stake in the company, is part of its plan to expand beyond its traditional focus on biomarker discovery and diagnostics development to become a "health information company" that can "provide actionable medical information to patients, physicians, and researchers," said an official.

The firms are building on a collaboration from last year, under which they unraveled the first X-ray structure of a DNA aptamer bound to its protein target.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.